FCM
CPRX

Fieldview Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Fieldview Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$572K Buy
+18,202
New +$537K 0.16% 204
2025
Q4 		– Sell
-16,514
Closed -$325K – 511
2025
Q3 		$325K Sell
16,514
-52,261
-76% -$1.07M 0.05% 321
2025
Q2 		$1.49M Buy
68,775
+50,923
+285% +$1.2M 0.23% 154
2025
Q1 		$433K Buy
+17,852
New +$402K 0.06% 296

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fieldview Capital Management's CPRX Position: Q2 2026 in Review

Fieldview Capital Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 18,202 shares worth $572K. The stake represents 0.16% of the portfolio and ranks #204 among its holdings. This is a return to the name: Fieldview Capital Management previously reported a position in CPRX as recently as Q3 2025.

Fieldview Capital Management first reported a position in CPRX in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.49M in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Fieldview Capital Management held 18,202 shares of Catalyst Pharmaceutical worth $572K as of Q2 2026.
  • Catalyst Pharmaceutical was a new Fieldview Capital Management position in Q2 2026.
  • Catalyst Pharmaceutical made up 0.16% of Fieldview Capital Management's portfolio in Q2 2026, its #204 holding.
  • Fieldview Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 4 quarters since.
  • Fieldview Capital Management's Catalyst Pharmaceutical position peaked at $1.49M in Q2 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.